Typed or printed name

Bonnie Stein

120 1 2 2004

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of Information unless it displays a velid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co Application Number 10/607,521 TRANSMITTAL Filing Date June 26, 2003 First Named Inventor FORM Stefan SCHÄFER et al. Art Unit Examiner Name HENLEY, Raymond J. III (to be used for all correspondence after initial filing) Altomey Docket Number DEAV2002/0044 US NP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittat Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a ~ After Final Provisional Application Proprietary Information Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Endosure(s) (please identify Extension of Time Request Terminal Disclaimer below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Attachments: Reply to Missing Parts/ 1) Amendment Pursuant to 37 C.F.R. 1.121 (c) and Response AFter Final Pursuant to 37 Incomplete Application C.F.R. 1.116 - 8 pgs. Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Lawrence L. Martin Date Reg. No. December 13, 2004 46,902 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 .; Total No. of Pages Transmitted; _ Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

December 13, 2004

Let 1 5 2004

PATENT

Docket No.: DEAV2002/0044 US NP IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Raymond J Henley III

Schafer et al.

Filed:

Art Unit:

1614

Serial No.: 10/607,521

06/26/2003

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted vin factimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703-872-9306, cm

Title: Use of Vasopeptidase Inhibitors in the

Date of Deposit:

December 13, 2004

Treatment of Metabolic Diseases, Nephropathy and Advanced Glycation

Printed Name of Person Signing Certificate: Bonnic Stein

End-Product Associated Diseases

Signature

AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 (c) AND RESPONSE AFTER FINAL PURSUANT TO 37 C.F.R. § 1.116

Box Non-Fee Amendment Commissioner for Patents

Washington, D.C. 20231

Sir:

This is a supplemental response in response to the Advisory Action issued in connection with the outstanding Final Office Action, dated September 14, 2004, for which a response is due by December 14, 2004, and Applicants' response of November 19, 2004, in the above-identified patent application. Applicants respectfully request entry of the following remarks and amendments. Applicants request reconsideration and withdrawal of all outstanding rejections in light of the aforesaid remarks and amendments.